The FDA has approved a reduction in the recommended monitoring time for the first two doses of Amgen's IMDELLTRA, a treatment for extensive-stage small cell lung cancer (ES-SCLC), from 22-24 hours to 6-8 hours. This change allows patients to spend less time in healthcare settings during initial treatment, potentially easing the treatment burden and making it more accessible in community oncology practices. Patients will still receive follow-up assessments the day after these doses. This update reflects Amgen's commitment to improving patient care and may enable more patients to receive treatment closer to home.
Investors in the Schwab U.S. Dividend Equity ETF (SCHD) who reinvested dividends over the past decade earned about $1.03 million from a $300,000 investment, trailing the S&P 500 index's $1.25 million by over $216,000. Despite a low expense ratio of 0...
Amgen announced it will present at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026. Key executives Jay Bradner and Thomas Dittrich will discuss the company's research, development, artificial intelligence initiatives...
